Login to Your Account

Tivo replay: EU deal affirms near-term plan for Aveo in RCC

By Jennifer Boggs
Managing Editor

Monday, December 21, 2015

Aveo Oncology Inc. signed up specialty cancer firm Eusa Pharma Ltd. as its European partner for its VEGF tyrosine kinase inhibitor, tivozanib, in a deal that helps validate the biotech’s continued push for the beleaguered cancer drug, which might finally be approaching the finish line, at least in Europe.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription